229 related articles for article (PubMed ID: 22924391)
1. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Marchand T; Revest M; Tattevin P; Chevrier S; Poullot E; Lamy T; Houot R
Leuk Lymphoma; 2013 Mar; 54(3):643-5. PubMed ID: 22924391
[No Abstract] [Full Text] [Related]
2. [Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Ettahar N; Legout L; Ajana F; Patoz P; Massongo M; Rose C; Senneville E
J Mycol Med; 2013 Mar; 23(1):57-63. PubMed ID: 23375857
[TBL] [Abstract][Full Text] [Related]
3. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Tsukasaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
[No Abstract] [Full Text] [Related]
4. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Herold T; Seiler T; Egensperger R; Trumm C; Bergmann M; Franke D; Mumm FF; Schinwald N; Buske C; Dreyling M
Leuk Lymphoma; 2012 Jan; 53(1):169-72. PubMed ID: 21812535
[No Abstract] [Full Text] [Related]
5. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT; Hillmen P; Hellmann A; Robak T; Hughes SG; Trone D; Shannon M; Flinn IW; Byrd JC;
Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
[TBL] [Abstract][Full Text] [Related]
7. Cryptococcus neoformans var neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia.
Assing K; Birgens H; Arendrup M
Clin Microbiol Infect; 2003 May; 9(5):441-4. PubMed ID: 12848761
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
[No Abstract] [Full Text] [Related]
9. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Casak SJ; Lemery SJ; Shen YL; Rothmann MD; Khandelwal A; Zhao H; Davis G; Jarral V; Keegan P; Pazdur R
Oncologist; 2011; 16(1):97-104. PubMed ID: 21212432
[TBL] [Abstract][Full Text] [Related]
10. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
12. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
13. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
Sarid N; Eshel R; Rothman R; Shpringer M; Perry C; Solar I; Dezorella N; Gepstein L; Canaani J; Naparstek E; Polliack A; Herishanu Y
Eur J Haematol; 2012 Nov; 89(5):430-1. PubMed ID: 22816611
[No Abstract] [Full Text] [Related]
16. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U
Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
[TBL] [Abstract][Full Text] [Related]
18. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Fink AM; Böttcher S; Ritgen M; Fischer K; Pflug N; Eichhorst B; Wendtner CM; Winkler D; Bühler A; Zenz T; Staib P; Mayer J; Hensel M; Hopfinger G; Wenger M; Fingerle-Rowson G; Döhner H; Kneba M; Stilgenbauer S; Busch R; Hallek M
Leukemia; 2013 Sep; 27(9):1949-52. PubMed ID: 23787395
[No Abstract] [Full Text] [Related]
19. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
20. Case 4: Weakness and Headaches in a 14-year-old Boy.
White A; Liu X; Das SU
Pediatr Rev; 2018 Aug; 39(8):424-426. PubMed ID: 30068745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
